Fractionation, structural studies, and immunological characterization of the semi-synthetic Quillaja saponins derivative GPI-0100

Vaccine

Volumn 21, Issue 25-26, 2003, Pages 3961-3971

  Marciani, Dante J ^a   Reynolds, Robert C ^b   Pathak, Ashish K ^b   Finley Woodman, Kyra ^a   May, Richard D ^b  

^a Galenica Pharmaceuticals Incorporated   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

Adjuvant; GPI 0100; Quillaja saponins; Saponin analogs

Indexed keywords

AMIDE; GAMMA INTERFERON; GLUCURONIC ACID; GPI 0100; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; N DICYCLOHEXYLUREA; SAPONIN DERIVATIVE; UFGPI 0100; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ACYLATION; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEACYLATION; DRUG ANALYSIS; FEMALE; FRACTIONATION; IMMUNITY; IMMUNOLOGY; IMMUNOSTIMULATION; MICELLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSED PHASE LIQUID CHROMATOGRAPHY; TH1 CELL; TH2 CELL;

QUILLAJA;

EID: 0141882443     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00298-6     Document Type: Article

References (27)

1. Kensil C.R., Patel U., Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol. 146:1991;431-437.
2. HogenEsch H. Mechanism of stimulation of the immune response by aluminum adjuvants. Vaccine. 20:2002;S34-S39.
3. Soltysik S., Wu J.-Y., Recchia J., Wheeler D.A., Newman M.J.et al. Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine. 13:1995;1403-1410.
4. Press J.B., Reynolds R.C., May R.D., Marciani D.J. Structure/function relationships of immunostimulating saponins. Stud. Nat. Prod. Chem. 24:2000;131-174.
5. Kensil C.R., Wu J.Y., Anderson C.A., Wheeler D.A., Amsden J. QS-21 and QS-7: purified saponin adjuvants. Dev. Biol. Stand. 92:1998;41-47.
6. Marciani D.J., Pathak A.K., Reynolds R.C., Seitz L., May R.D. Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins. Int. Immunopharmacol. 1:2001;813-818.
7. Higuchi R., Tokimitsu Y., Fujioka T., Komori T., Kawasaki T.et al. Structure of desacylsaponins obtained from the bark of Quillaja saponaria. Phytochemistry. 26:1987;229-235.
8. Kensil C, Soltysik S, Patel U, Marciani DJ. Structure-function relationship in adjuvants from Quillaja saponaria Molina. In: Brown F, Chanock RM, Ginsberg HS, Lerner RA, editors. Vaccine 92. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1992. p. 35-40.
9. Marciani D.J., Ptak R.G., Voss T.G., Reynolds R.C., Pathak A.K.et al. Degradation of Quillaja saponaria Molina saponins: loss of the protective effects of a herpes simplex virus 1 sub-unit vaccine. Int. Immunopharmacol. 2:2002;1703-1711.
10. Marciani D.J., Press J.B., Reynolds R.C., Pathak A.K., Pathak V.et al. Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity. Vaccine. 18:2000;3141-3151.
11. Liu G., Anderson C., Scaltreto H., Barbon J., Kensil C.R. QS-21 structure/function studies: effects of acylation on adjuvant activity. Vaccine. 20:2002;2808-2815.
12. Marciani D.J., Pathak A.K., Reynolds R.D. Quillaja saponin adjuvants: derivatives formed under sub-optimal conditions. Vaccine. 20:2002;3237-3238.
13. Soltysik S., Bedore D.A., Kensil C.R. Adjuvant activity of QS-21 isomers. Ann. New York Acad. Sci. 690:1993;392-395.
14. Nord L.I., Kenne L. Separation and structural analysis of saponins in a bark extract from Quillaja saponaria Molina. Carbohydr. Res. 320:1999;70-81.
15. So H.S., Yoon H.S., Choi D.Y., Kwon Y.S., Sung J.H.et al. Effect of a novel saponin adjuvant derived from Quillaja saponaria on the immune response to recombinant hepatitis B surface antigen. Mol. Cells. 7:1997;178-186.
16. Guo S., Kenne L., Lundgren L.N., Ronnberg B., Sundquist B.G. Triterpenoid saponins from Quillaja saponaria. Phytochemistry. 48:1998;175-180.
17. Rhodes J. Covalent chemical events in immune induction: fundamental and therapeutic aspects. Immunol. Today. 17:1996;436-441.
18. Chen H., Rhodes J. Schiff base forming drugs. Mechanisms of immune potentiation and therapeutic potential. J. Mol. Med. 74:1996;497-504.
19. Guo S., Kenne L. Structural studies of triterpenoid saponins with new acyl components from Quillaja saponaria Molina. Phytochemistry. 55:2000;419-428.
20. Kensil CR, Wu J-Y, Soltysik S. Structural and immunological characterization of the vaccine adjuvant QS-21. In: Powell MF, Newman MJ, editors. Vaccine design: the subunit and adjuvant approach. New York: Plenum Press; 1995. p. 525-41.
21. Livingston P.O., Adluri S., Helling F., Yao T.J., Kensil C.R.et al. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine. 12:1994;1275-1280.
22. O'Hagan DT. Recent advances in vaccine adjuvants for systemic and mucosal administration. J Pharm Pharmacol 1998;49:1-10.
23. Carlson B.C., Jansson A.M., Larsson A., Butch A., Lorentzen J.C. The endogenous adjuvant squalene can induce a chronic T-cell mediated arthritis in rats. Am. J. Pathol. 156:2000;2057-2065.
24. Holm B.C., Svelander L., Butch A., Lorentzen J.C. The arthritogenic adjuvant squalene does not accumulate in joints, but gives rise to pathogenic cells in both draining and non-draining lymph nodes. Clin. Exp. Immunol. 127:2002;430-435.
25. Glueck R. Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization. Vaccine. 20:2002;S42-S44.
26. Del Giudice G., Podda A., Rappuoli R. What are the limits of adjuvanticity? Vaccine. 20:2002;S38-S41.
27. Ragupathi G., Coltart D.M., Williams L.J., Koide F., Kagan E.et al. On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines. Proc. Natl. Acad. Sci. U.S.A. 99:2002;13699-13704.